RA’ANANA, Israel & NEW YORK--(BUSINESS WIRE)--Nov. 6, 2018--
UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will
present at two investor conferences in November 2018:
-
Stifel 2018 Healthcare Conference
-
Tuesday, November 13
-
9:30AM Eastern Time
-
New York, NY
-
Jefferies 2018 London Healthcare Conference
-
Thursday, November 15
-
9:20AM Greenwich Mean Time
-
London, UK
A live audio webcast of each event will be available on the Investors
section of UroGen's website, www.urogen.com.
A replay of each webcast will be available on the website for
approximately two weeks.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical
company developing advanced non-surgical treatments to address unmet
needs in the field of urology, with a focus on uro-oncology. UroGen has
developed RTGel™, a proprietary sustained release, hydrogel-based
platform technology that has the potential to improve therapeutic
profiles of existing drugs. UroGen’s sustained release technology is
designed to enable longer exposure of the urinary tract tissue to
medications, making local therapy a potentially more effective treatment
option. UroGen’s lead product candidates, UGN-101 and UGN-102, are
designed to potentially remove tumors by non-surgical means and to treat
several forms of non-muscle invasive urothelial cancer, including
low-grade upper tract urothelial carcinoma and bladder cancer,
respectively. UroGen is headquartered New York, NY with offices in
Ra’anana, Israel and Los Angeles, CA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181106005059/en/
Source: UroGen Pharma Ltd.
UroGen Pharma Ltd.
Kate Bechtold, 914-552-0456
Director,
Corporate Communications & Investor Relations
Kate.Bechtold@urogen.com
